Introduction/Background Breast cancer is a heterogeneous disease. Liminal breast cancer (A and B) is defined by the presence of hormone receptor (HR) expression with the absence or overexpression of HER2.

Receptor These subtypes of breast cancer are known for their Favourable prognosis, and the main validated systemic treatment is Hormone therapy.

Methodology We conducted a retrospective study of 27 cases of luminal metastatic breast cancer followed up in the gyneco-oncology department of the CHU IBN ROCHD in CASABLANCA. Our study’s objective was to investigate epidemiological and clinical, anatomical, pathological, therapeutic, evolutionary, prognostic and predictive characteristics of the cases.

Results A peak in frequency was noted between 40 and 49 years of age, with a personal history of breast cancer, as well as family history of hormone-dependent cancers.

Infiltrating ductal carcinoma was the most common type, accounting for 74% of cases. Molecular classification, luminal type B HER 2-negative is the most common found in 92.6% of cases.

Therapeutically, the indication for surgical castration was primarily a metastatic lesion. This is the case in 23 patients with metastatic breast cancer, who are young women in their Genital Activity Period with a positive hormone receptor, and are associated with chemical hormone therapy based on anti-aromatase.

In the second row, the menstrual cycle resumption occurs after tamoxifen treatment. This is the case in four patients with metastatic recurrence who initially benefited from surgery, chemotherapy, radiation therapy, and chemical hormone therapy based on tamoxifen.

Surgical castration was performed in all patients by laparoscopic route allowing the discovery of malignant ovarian lesions.

Conclusion The diagnostic value of surgical castration is not being studied as much as it should and there is a lack of data in the literature.

Disclosures Nothing to disclose.